ArticleFrontiers in chemistry2022
Ruthenium polypyridine complexes with triphenylamine groups as antibacterial agents against
Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Amphiphile-Assisted Synthesis of Ruthenium Nanoparticles for Controlled Release and Enhanced Antibacterial Activity.Small methods · 2025Article
- Novel ruthenium(II) polypyridyl complexes conjugated with bis-dipicolylamine as antibacterial photosensitisers.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2025Article
- Design and synthesis of bioactive Ru(ii) complexes: antibacterial activity, biocompatibility and biomolecular binding.RSC advances · 2025Article
- Research on the application of a high-throughput fully automated bacterial growth curve monitor for screening natural antibacterial compounds.BMC microbiology · 2025Article
- Impact of LiveMicroorganisms · 2025Article
- The biosynthesis of trillin 6'-Synthetic and systems biotechnology · 2025Article
- Comprehensive safety and toxicity analysis of 2,2'-Bipyridine derivatives in combating MRSA biofilm formation and persistence.Frontiers in cellular and infection microbiology · 2025Article
- Morpholine-modified Ru-based agents with multiple antibacterial mechanisms as metalloantibiotic candidates againstRSC advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the emergence and wide spread of methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.